1. Home
  2. NL vs IFRX Comparison

NL vs IFRX Comparison

Compare NL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NL Industries Inc.

NL

NL Industries Inc.

N/A

Current Price

$6.89

Market Cap

283.1M

Sector

Industrials

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$2.30

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NL
IFRX
Founded
1891
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
303.4M
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
NL
IFRX
Price
$6.89
$2.30
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
41.0K
976.3K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
10.22%
N/A
EPS Growth
N/A
N/A
EPS
0.27
N/A
Revenue
$158,285,000.00
N/A
Revenue This Year
$9.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.00
N/A
Revenue Growth
8.46
N/A
52 Week Low
$5.04
$0.80
52 Week High
$8.60
$2.95

Technical Indicators

Market Signals
Indicator
NL
IFRX
Relative Strength Index (RSI) 64.35 60.09
Support Level $5.67 $2.25
Resistance Level $8.60 $2.57
Average True Range (ATR) 0.21 0.16
MACD 0.02 0.01
Stochastic Oscillator 77.11 59.60

Price Performance

Historical Comparison
NL
IFRX

About NL NL Industries Inc.

NLI Holdings Inc, formerly known as NL Industries Inc, is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: